2026-04-05T10:47:56Zhttps://recercat.cat/oai/requestoai:recercat.cat:2072/4779522025-02-25T19:08:17Zcom_2072_98col_2072_378192
Unrelated Cord Blood Transplantation for Patients with Primary or Secondary Myelofibrosis
Robin, Marie
Giannotti, Federica
Deconinck, Eric
Mohty, Mohamad
Michallet, Mauricette
Sanz, Guillermo
Chevallier, Patrice
Cahn, Jean-Yves
Legrand, Faezeh
Rovira, Montserrat
Passweg, Jakob
Sierra, Jorge
Nguyen, Stephanie
Maillard, Natacha
Yakoub-Agha, Ibrahim
Linkesch, Werner
Cannell, Paul
Marcatti, Magda
Bay, Jacques Olivier
Chalandon, Yves
Kröger, Nicolaus
Gluckman, Eliane
Rocha, Vanderson
Olavarria, Eduardo
Ruggeri, Annalisa
Universitat Autònoma de Barcelona. Departament de Medicina
Myelofibrosis
Umbilical cord blood transplantation
To determine whether umbilical cord blood transplantation (UCBT) is an alternative cure for myelofibrosis (MF), we evaluated 35 UCBTs reported to Eurocord. Seven patients had secondary acute myeloid leukemia (AML) at UCBT, and median age at UCBT was 54 years. Twenty-four patients received a reduced-intensity conditioning (RIC) regimen, and 17 of 35 patients received total body irradiation (2 to 12 Gy)-fludarabine-cyclophosphamide (TCF) conditioning. The median follow-up was 24 months. The cumulative incidence of neutrophil recovery at 60 days was 80%. Fifteen patients relapsed after UCBT. The 2-year overall survival and event-free-survival (EFS) rates were 44% and 30%, respectively. All patients given TCF achieved neutrophil and platelet recovery, and the use of TCF was associated with superior EFS in the RIC population (44% versus 0%, P=.001). Patients with transformation to AML had similar outcomes to patients with less advanced stages. In conclusion, despite graft failure remaining a major concern, the role of UCBT in the management of MF, especially using RIC TCF-based regimens, deserves further investigation to improve results.
2014
Article
Biology of blood and marrow transplantation ; Vol. 20 Núm. 11 (january 2014), p. 1841-1846
open access
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
https://creativecommons.org/licenses/by-nc-nd/4.0/